Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity - eBioMedicine
Por um escritor misterioso
Descrição
Biomedicines, Free Full-Text
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab. - Abstract - Europe PMC
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity - eBioMedicine
Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma. - Abstract - Europe PMC
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity - eBioMedicine
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity - eBioMedicine
Preclinical Anti-Tumor Activity of Hexabody-CD38 in Patient-Derived B Cell Lymphoma and Acute Myeloid Leukemia Xenograft Models - ScienceDirect
Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma. - Abstract - Europe PMC
Crystal structure of CD38 in complex with daratumumab, a first-in-class anti -CD38 antibody drug for treating multiple myeloma - ScienceDirect
de
por adulto (o preço varia de acordo com o tamanho do grupo)
